doxycycline

(redirected from Periostat)
Also found in: Thesaurus, Medical, Wikipedia.
Related to Periostat: doxycycline, Atridox

dox·y·cy·cline

 (dŏk′sĭ-sī′klēn′, -klĭn)
n.
A broad-spectrum antibiotic, C22H24N2O8, derived from tetracycline.

doxycycline

(ˌdɒksɪˈsaɪklɪn)
n
1. (Medicine) a tetracycline antibiotic used to treat conditions caused by a wide range of bacteria, including anthrax
2. (Pharmacology) a tetracycline antibiotic used to treat conditions caused by a wide range of bacteria, including anthrax
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.doxycycline - an antibiotic derived from tetracycline that is effective against many infections; "Vibramycin is the trade name of doxycycline"
antibiotic, antibiotic drug - a chemical substance derivable from a mold or bacterium that can kill microorganisms and cure bacterial infections; "when antibiotics were first discovered they were called wonder drugs"
Translations
doxycyklin

doxycycline

n doxiciclina
References in periodicals archive ?
Fowler is on the speakers' bureau for CollaGenex, which markets Periostat.
An open-label study and two ongoing studies funded by CollaGenex indicate that Periostat can treat and manage the symptoms of rosacea.
In the MIDAS (Metalloproteinase Inhibition with Low-Dose Doxycycline to Prevent Acute Coronary Syndromes) pilot trial, Periostat not only lowered levels of CRP, but also reduced levels of the inflammatory cytokine interleukin (IL)-6, which is implicated in CRP production and the occurrence of acute coronary events.
Golub, DMD, MSC, honorary MD, professor in Oral Biology and Pathology, State University of New York (SUNY) at Stony Brook, and colleagues, researchers found that not only did Periostat lower levels of MMP-9 protein, but it also inhibited its activity.
2 million of Periostat net sales, $128,000 in contract revenues and $100,000 in licensing fees.
5 million in net sales of Periostat and $650,000 of contract revenues.
After careful consideration, we have concluded that CollaGenex' shareholders will be best served if we develop the dermatological indications for Periostat ourselves," said Brian M.
In September 2001, CollaGenex announced the results from a 60-patient, double-blinded, placebo-controlled clinical trial designed to evaluate the efficacy of Periostat to treat adult patients with acne.
2 million for the third quarter of 1999, which represented a 31% increase over Periostat net sales in the second quarter of 1999.
The company recently announced that an agreement had been reached with the FDA with respect to the continuing review of the Periostat NDA.
launch of Periostat, a new product pending FDA approval for the treatment of periodontal disease.
CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues and by enhancing bone protein synthesis, and Atridox(R), Atrisorb FreeFlow(R) and Atrisorb-D FreeFlow(R), which are products of QLT Inc.